ClinicalTrials.gg
CompletedNCT01230138Updated Dec 11, 2012

Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis

A Phase 2 interventional study of Placebo and FP187 in Plaque Psoriasis, sponsored by Forward-Pharma GmbH. Completed at 2 sites in Germany. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2012-12-11.

Sponsored by Forward-Pharma GmbH · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 299 studies in Psoriasis with a site in Germany — 13 open to participants now, 30 under way, 15 of them phase 3. Psoriasis · Germany.

Enrollment
112th of 260
252 · median 196
Started
2010
with 16 others
Phase 2
74 of 299
1 open now
Registered
67th of 299
by date

Among the 299 studies in Psoriasis with a site in Germany, this one is the 112th largest by enrollment of the 260 interventional ones that give a count, is one of 17 that started in 2010, is one of 74 in phase 2, and was the 67th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

13 of the 299 studies in Psoriasis with a site in Germany are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 299 studies in Psoriasis with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this trial is to investigate the efficacy and safety of different doses and dose administrations of FP187 compared to a placebo treatment in patients with moderate to severe plaque psoriasis.

Read the detailed description

The trial tests two different dose levels and two different daily dosing schedules (twice daily (BID) and three times daily (TID))over 20 weeks of treatment. Key is effect as measured by achievement of a 75% reduction in PASI after 20 weeks and safety monitored by adverse events and safety lab.

There are 3 active arms:

  1. FP-187 at a daily dose of 750mg divided in three doses (250mg TID)
  2. FP-187 at a daily dose of 750mg divided in two doses (375mg BID)
  3. FP-187 at a daily dose of 500mg divided in two doses (250mg BID)

and 1 placebo arm.

An additional open (flexible dosing) treatment arm has been amended to the trial

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of either sex at least 18 years of age
  • A clinical diagnosis of plaque psoriasis defined as skin areas with erythema, induration and scaling, with a body surface area of no less than 10% and in total to be scoring at least 10 on the PASI scale
  • The psoriasis disease have been stable for at least 6 months at randomization
  • Signed and dated
  • Sexually active females of must be either surgically sterile (hysterectomy or tubal ligation) or use a highly effective (failure rate \< 1%) medically accepted method during the trial as well as one month after trial is finished such as:

    • Systemic contraceptive (oral, implant, injection),
    • Intrauterine device (IUD) inserted for at least one month prior to study entrance
  • Willingness and ability to comply with the trial procedures
  • Patient is beside the psoriasis disease in good general health in the opinion of the Investigator, as determined by medical history, physical examination, vital signs and clinical laboratory parameters (hematology, biochemistry and urinalysis).

Exclusion criteria

Exclusion Criteria:

  • Female patients who are pregnant or breast-feeding or planning to become pregnant up to 7 months from treatment start as well as male patients plan-ning pregnancy with their partner up to 7 months from treatment start or practise unprotected sexual relationship up to 7 months from treatment start
  • Known allergy to any of the constituents of the product being tested
  • Pustular forms of psoriasis, erythrodermic or guttate psoriasis
  • Known diseases (e.g., AIDS/)
  • Presence of another serious or progressive disease which, according to the Investigator may interfere with treatment outcome
  • Active skin disease such as atopic dermatitis, rosacea, lupus erythematosus, or other inflammatory or infectious skin disease which, according to the Investigator may interfere with treatment outcome
  • Use of topical medical treatment or UVB treatment - Use of systemic anti-psoriatic treatment preceding the baseline visit Methotrexate, cyclosporine, or PUVA treatment within x weeks; Biological treatment (efalizumab, adalimumab, infliximab, etanercept) within xx weeks; Acitretin within x months; Treatment with Fumaderm® or other DMF containing products during past xx weeks prior to baseline visit; Discontinuation of previous treatment with Fumaderm® or other DMF containing products due to lack of efficacy or side effects;
  • Has within the past x weeks prior to baseline visit been treated with drugs influencing the course of the psoriasis such as antimalarial drugs, beta-blockers or lithium
  • Has a relevant clinical history of stomach or intestinal problems (eg gastritis or peptic ulcer within the last 10 years )
  • Has liver enzyme measures (, ALT, Gamma-GT) higher than 2x UNL)
  • Has an estimated : \< xx ml/min
  • Has leucopenia (leukocyte count \< x/mm3) or eosinophilia (count >x/µl) or lymphopenia (count \< x/nl).
  • Has protein in the urine test at screening or baseline visit
  • Participation in another clinical trial during the last month preceding the baseline visit or participation in a trial with treatment of biologicals within x months prior to baseline visit
  • Patients who are involved in the organisation of the clinical investigation or are in any way dependant on the investigator or sponsor
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
252 participants (actual)

Study arms

  • Experimental
    FP187 - TID

    FP187 250mg TID (total daily dose of 750mg)

    Drug: FP187

  • Experimental
    FP187- BID

    FP187 375mg BID (total daily dose of 750mg)of 750mg administered as 375mg BID

    Drug: FP187

  • Experimental
    FP187-LD-BID

    FP187 250mg BID (total daily dose of 500mg)

    Drug: FP187

  • Placebo comparator
    Placebo

    Placebo treatment

    Drug: Placebo

  • Experimental
    Open, flexible dosing treatment arm

    Open treatment using a flexible dosing schedule for 8 weeks with maximum dose of 750mg FP187 and with a total dosing of 20 weeks. All investigations following same schedule.

    Drug: FP187

Interventions

  • DrugPlacebo

    Placebo tablets

    Also known as: Placebo of FP187

  • DrugFP187

    High daily dose of 750mg administered as 250mg TID

  • DrugFP187

    High daily dose of 750mg administered as 375mg BID

  • DrugFP187

    Low daily dose of 500mg FP187 administered as 250mg BID

  • DrugFP187

    Oral tablets, up to 3 times daily for 20 weeks.

06

What researchers measure

Primary outcomes

  1. Proportion of patients achieving PASI 75 compared to placebo

    Proportion of patients achieving PASI75 (a reduction in the PASI score of 75% or more)

    Time frame: After 20 weeks of treatment

Secondary outcomes

  1. PASI 75

    Proportion of patients achieving PASI75 (a reduction of the PASI score of 75% or more compared to baseline)

    Time frame: At week 4, 8, 12 and 16

  2. PASI 50

    Proportion of patients who achieves PASI 50 (a reduction of the PASI score of 50% or more compared to baseline)

    Time frame: At week 4, 8, 12, 16 and 20

  3. PASI 90

    Proportion of patients achieving PASI90 (a reduction of the PASI score of 90% or more compared to baseline

    Time frame: At week 4, 8, 12, 16 and 20

  4. PGA (Physicians Global Assessment)

    On a 5-point scale from 0 (abscence or very mild disease) to 4 (very severe disease) proportion of patients being responders - defined as patients achieving either a score of 0 or 1 or a two point improvement

    Time frame: At week 4, 8, 12, 16 and 20

  5. PaGA (Patients Global Assessment

    Patients evaluation on a 5-point Likert scale 1 (very good) - 5 (very poor)based on the evaluation of: "Considering all the ways your psoriasis affects you, how have you been doing in the last 24 hours?"

    Time frame: At week 4,8,12,16 and 20

  6. Pruritus

    Patient evaluation of pruritus measured on a VAS (Visual Analog Scale) from 0mm (no pruritus) to 100mm (worst possible pruritus)

    Time frame: At week 4, 8, 12, 16 and 20

  7. Patient rated QoL (Quality of Life)

    Patient filling in 10 questions on the DLQI QoL system with a calculated summary score and analysis of the improvement from baseline

    Time frame: At week 4, 8, 12, 16 and 20

  8. Adverse events (AEs)

    Summary of incidense and severity of AEs and ADRs (Adverse Drug Reactions)/SAEs (Serious Adverse Events)/SUSARs (Suspected Unexpected Serious Adverse Reactions)

    Time frame: At week 4, 8, 12, 16 and 20

  9. Safety lab test

    Summary of lab parameters and clinically relevant changes over the treatment period in standard clinical chemistry tests, standard haematology tests and urin dip stick test

    Time frame: At week 20

07

Study locations

2 sites
  • Dermatological Dept., Uniklinikum, TU-Dresden
    Dresden, 01307, Germany
  • SCIderm
    Hamburg, 20354, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Jan 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2010
First posted
Oct 28, 2010
Start
Sep 2010
Primary completionActual
Jan 2012
CompletionActual
May 2012
Last update
Dec 11, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01230138
Lead sponsor
Forward-Pharma GmbH
Responsible party
Sponsor
First posted
Oct 28, 2010
Start date
Sep 2010
Primary completion
Jan 2012
Completion
May 2012
Last update
Dec 11, 2012

Study contacts

Peder M Andersen, MD
study director · Forward-Pharma GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion